Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: In some examples, a fluid ejection assembly is removably mountable in a system, and includes a fluid ejection device, and a removable frame on which the fluid ejection device is mounted. The removable frame includes a plurality of fluid interface members that share a common design to releasably engage with a plurality of fluid interface connectors together as the removable frame is brought into engagement with a support structure in the system and on which the plurality of fluid interface connectors are mounted. Engagement of a first fluid interface member with a first fluid interface connector establishes a gas path through the first fluid interface member and the first fluid interface connector, and engagement of a second fluid interface member with a second fluid interface connector establishes a liquid path through the second fluid interface member and the second fluid interface connector, the liquid path to deliver a liquid to the fluid ejection device.

Abstract: The present patent application discloses at least the compounds according to Formula l shown below, or pharmaceutically acceptable salts thereof, wherein ringjB,n, JD, J,0, X, X1, J, RC, and W are as defined herein. These compounds are useful as simulators of soluble sGC.

Abstract: Apparatus and methods for measurement of pore pressure in rock formations through an open, or cemented and/or cased, borehole are described. Such measurements are achieved using the Dynamic Acoustic Elasticity (DAE) method for characterizing nonlinear parameters by perturbing a selected rock formation volume with a High Amplitude, Low Frequency (HALF) acoustic strain wave, and probing this volume using a Low Amplitude, High Frequency (LAHF) acoustic wave. Time reversal techniques may be employed for focusing acoustic energy Into the formation in the vicinity of the pipe or open hole.

Abstract: The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of Nonalcoholic Steatohepatitis (NASH).

Abstract: A mechanical fastener for an electrical interface may include a first handle and a second handle The first handle and second handle are located on opposite sides of the mechanical fastener. The mechanical fastener may also include a first housing, a second housing coupled to the first housing, an electrical interface housed in the mechanical fastener between the first and second housings, a first lever intermediary between the first handle and the first housing and mechanically coupled to the second handle, a second lever intermediary between the second handle and the second housing and mechanically coupled to the first handle, a first post coupled to the first handle and the second lever, and a second post coupled to the second handle and the first lever.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

Abstract: In some examples a printing system includes purging manifolds. The printing system includes a fluid ejection device to dispense a fluid and a first reservoir to house a fluid. The system further includes a purging manifold to fluidically couple to the fluid ejection device, and the purging manifold to fluidically couple to the first reservoir. The purging manifold includes a second reservoir. The purging manifold further includes a supply port; a fluid inlet port; and a purging outlet port. The purging outlet port is disposed above the supply port to convey fluid to the first reservoir. The printing system also includes a fluid interface connector to fluidically connect to the supply port and fluidically connect to the fluid ejection device.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I.

Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: A print liquid supply apparatus or interface structure to be connected to a print system comprises a liquid channel, liquid interface and integrated circuit contact pads.

Abstract: In some examples, a fluid ejection assembly is removably mountable in a system, and includes a fluid ejection device, and a removable frame on which the fluid ejection device is mounted. The removable frame includes a plurality of fluid interface members that share a common design to releasably engage with a plurality of fluid interface connectors together as the removable frame is brought into engagement with a support structure in the system and on which the plurality of fluid interface connectors are mounted. Engagement of a first fluid interface member with a first fluid interface connector establishes a gas path through the first fluid interface member and the first fluid interface connector, and engagement of a second fluid interface member with a second fluid interface connector establishes a liquid path through the second fluid interface member and the second fluid interface connector, the liquid path to deliver a liquid to the fluid ejection device.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

Abstract: A method and apparatus for constructing a folded flat. The flat may include a first surface having a first panel and a second panel. Each of the first panel and the second panel include an inner edge. Further, the first panel may include a first score line that extends in the machine direction and a tab adjacent the first score line. The tab connects the first panel and the second panel. A folding apparatus may engage the first surface of the flat. The folding apparatus may include an engagement member and a fold assist member. The fold assist member may engage the area between the inner edge of the first panel and the inner edge of the second panel. The engaging member and the fold assist member cooperate fold the flat along the score line to form a folded flat.

Abstract: A positioning determination method using an improved RFID location tag is described the tag including an RFID controller; memory; a power management module; and an accelerometer. The position determination method including the steps of periodically polling the RFID tags for information; receiving information from a plurality of reference RFID tags at a known location; receiving information from the non reference RFID tags, the information including the tag id and sensor data; calculating for each non reference and referenced RFID tag a received signal strength indication; and calculating an initial position for each non reference RFID tag based on the received signal strength indications and the positions of the reference RFID tags.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.